Pharmaceutical/Biotechnology Deal Statistics Quarterly, Q3 2010
Biopharma financings slumped in the third quarter of 2010 - the $1.69 billion raised in Q3 was about half of Q2's $3.37 billion. Most of the third quarter money came from VC rounds. Two-thirds of the M&A total came from J&J's $2.2 billion purchase of the 82.1% of Crucell that it didn't already own. And following a long stretch in which earlier-stage assets were grabbing the largest deal values, Q3's biopharma alliances proved the contrary - the majority of the biggest moneymakers were for Phase II and higher therapeutics.
You may also be interested in...
Pharmaceutical companies are attempting to solve unprecedented R&D and commercial challenges via business development, emphasizing cheaper, earlier-stage alliances and building up a base in emerging markets. An analysis of dealmaking trends from 2007 to 2010 shows big companies are embracing new kinds of partners, and shifting away from historic areas of interest to pursue hyper-specialty products and generics.
In late September, Reata Pharmaceuticals Inc. dealt its Phase IIb chronic kidney disease candidate bardoxolone to Abbott Laboratories Inc., and the $450 million down payment easily dwarfs those on other deals around development-stage drug candidates, going back as far as the eye can see.
ZymoGenetics shareholders who want a better offer than the $885 million acquisition Bristol-Myers Squibb offered on Wednesday, September 8, aren’t likely to get one. It’s a disappointing result for a company with nearly 30 years of biotech discovery and grand ambitions behind it.